12:00 AM
May 10, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Prevatac exisulind: Completed Phase III trial enrollment

Cell Pathways Inc. (CLPA), Horsham, Penn.
Product: Prevatac exisulind
Business: Cancer
Therapeutic category: Apoptosis

Read the full 52 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >